Hemispherian AS, a Oslo, Norway-based preclinical pharmaceutical company focused on small molecule cancer therapeutics targeting the DNA damage response, raised NOK 12.5M (USD 1.4M) in seed funding.
The round was led by Meneldor, who partnered with Norwegian and American investors. Hemispherian AS added new board members Paul Lelieveld, Wolfram Eichner, and Frode Vartdal. These members will join Steven Powell, Dallas Hack and Masha Strømme.
The company intends to use the funds to expand its drug development activities and its preclinical pipeline and move its lead therapeutic compounds towards clinical development.
Hemispherian is an innovative pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX). GLIX compounds target the TET2 enzyme and activate the DNA damage response resulting in cancer cell death. The company’s lead compound, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma multiforme, a deadly cancer of the central nervous system and the leading cause of death by disease in children. Hemispherian is further focused on developing a companion diagnostic tool to support patient selection for optimal therapeutic response to GLIX1.
FinSMEs
06/05/2022